Skip to main content
. 2010 Nov 17;49(1):201–208. doi: 10.1128/JCM.01868-10

FIG. 2.

FIG. 2.

Selection of bevirimat resistance over time. Three independent mixed cultures (A, B, and C) of recombinant patient-derived viruses were passaged at the indicated concentrations of bevirimat, and the prevalences of unique combinations of bevirimat-associated resistance mutations were determined. Only drug concentrations that were amplifiable at all tested time points and only mutation profiles with at least 2% prevalence at any time point are shown.